Biophan Commencing Animal Trials of MRI-Visible Vena Cava Filter.

ROCHESTER, N.Y. -- Advanced Solution Expected to Boost Safety of Vena Cava Filter Procedures, Ushering in New Era of Interventional MRI 

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, today announced plans to begin animal trials of its advanced MRI-imageable vena cava filter, in a research program underway at the Company's newly established Biophan-Europe division. The announcement of the trials, anticipated to commence within the next quarter, was made by Michael Weiner, Chief Executive Officer of Biophan.

Vena cava filters are used in the main venous system, where they remain either temporarily or permanently, to trap circulating blood clots, plaque, or other materials that can cause life threatening lung embolisms. The Company's vena cava filter was developed at its Biophan-Europe division, a German company formerly known as AMRIS GmbH. Biophan recently acquired a controlling interest in the company, which is recognized as a leading innovator of medical devices and technology solutions compatible with Magnetic Resonance Imaging (MRI).

"The advanced vena cava technology is just one of the exciting pioneering research and development programs underway at Biophan-Europe, and is an excellent indication of the sort of work that made the acquisition of AMRIS so important to Biophan," said Mr. Weiner. "The solutions being developed at Biophan-Europe have significant implication for major sectors of the medical device marketplace."

Much of the technology under development at Biophan-Europe involves its "active" MRI solutions that use proprietary resonant frequency circuitry to enable superior functionality in MRI visualization. The Company's vena cava filter is unique in part because it enables physicians to use MRI to see inside the filter to determine if any clots or other materials have been trapped inside the filter, a capability almost impossible under x-ray visualization. This is currently the only filter that can be placed under MRI guidance, allows visualization of captured substrates, and subsequently removed.

Biophan's vena cava filter research program also breaks new ground in the field of interventional MRI; currently, the multi-billion-dollar MRI marketplace is almost entirely used to provide doctors with images for diagnostic purposes. Today, vena cava filters are mainly inserted through the femoral vein and placed in the inferior vena cava (IVC); the placement procedure is comparably simple, but currently must be conducted under x-ray guided visualization. This requires nephrotoxic and allergenic iodine-based contrast agents to be injected into the patient, and, as well, exposes patient and doctor to the x-ray radiation for the length of the procedure. Biophan's MRI-compatible devices could be inserted under MRI rather than x-rays, eliminating the dangers associated with x-rays.

"We believe this is the key technology to introduce MRI-guided vena cava filter placement into clinical routine," said Dr. Michael Friebe, CEO of Biophan-Europe.

"Researchers have long been interested in developing the field of Interventional MRI, but have been unable to make substantial headway. We are now in a position to start exploiting the potential for MRI to enable many helpful interventional and therapeutic procedures," added Prof. Andreas Melzer, chief researcher at the German subsidiary.

The Company will perform its testing in the next clinical trial phase on farm pigs, a standard animal model for experimentation. The Company's researchers intend to perform long-term, or chronic studies, expected to last from 28 to 90 days. The research program is being conducted in cooperation with the University of Essen, Germany (department of cardiology) and the University of Aachen, Germany (department of radiology).

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.